Circulating gamma glutamyltransferase and prediction of cardiovascular disease

Atherosclerosis

Volumn 238, Issue 2, 2015, Pages 356-364

  Kunutsor, Setor K ^a,b   Bakker, Stephan J L ^c,d   Kootstra Ros, Jenny E ^c   Gansevoort, Ronald T ^c   Dullaart, Robin P F ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

Author keywords

Cardiovascular disease; Gamma glutamyltransferase; Risk factor; Risk prediction

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; CYSTATIN C; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER; GAMMA-GLUTAMYLTRANSFERASE, HUMAN;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; WAIST CIRCUMFERENCE; AGED; BLOOD; CARDIOVASCULAR DISEASES; DECISION SUPPORT SYSTEM; ENZYME ASSAY; INCIDENCE; MIDDLE AGED; NETHERLANDS; PREDICTIVE VALUE; PROGNOSIS; RISK ASSESSMENT; TIME;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CLINICAL ENZYME TESTS; DECISION SUPPORT TECHNIQUES; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NETHERLANDS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84920894212     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.12.045     Document Type: Article

References (43)

1. Fraser A., Harris R., Sattar N., et al. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British women's heart and health study and meta-analysis. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2729-2735.
2. Wannamethee S.G., Lennon L., Shaper A.G. The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes. Atherosclerosis 2008, 201:168-175.
3. Ruttmann E., Brant L.J., Concin H., et al. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005, 112:2130-2137.
4. Kunutsor S.K., Apekey T.A., Khan H. Liver enzymes and risk of cardiovascular disease in the general population: a meta-analysis of prospective cohort studies. Atherosclerosis 2014, 236:7-17.
5. Ghouri N., Preiss D. and Sattar N., Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 52:1156-1161.
6. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N.Engl. J. Med. 2010, 363:1341-1350.
7. Mason J.E., Starke R.D. and Van Kirk J.E., Gamma-glutamyl transferase: a novel cardiovascular risk biomarker. Prev. Cardiol. 13:36-41.
8. Pencina M.J., D'Agostino R.B., Vasan R.S. Statistical methods for assessment of added usefulness of new biomarkers. Clin. Chem. Lab. Med. 2010, 48:1703-1711.
9. Pencina M.J., D'Agostino R.B., D'Agostino R.B., et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat. Med. 2008, 27:157-172. discussion 207-112.
10. Lee D.S., Evans J.C., Robins S.J., et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham heart study. Arterioscler. Thromb. Vasc. Biol. 2007, 27:127-133.
11. Harrell F.E., Lee K.L., Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 1996, 15:361-387.
12. Whitfield J.B. Gamma glutamyl transferase. Crit. Rev. Clin. Lab. Sci. 2001, 38:263-355.
13. Lambers Heerspink H.J., Brantsma A.H., de Zeeuw D., et al. Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am. J. Epidemiol. 2008, 168:897-905.
14. Borggreve S.E., Hillege H.L., Dallinga-Thie G.M., et al. High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides. Eur. Heart J. 2007, 28:1012-1018.
15. Dullaart R.P., Perton F., van der Klauw M.M., et al. High plasma lecithin:cholesterol acyltransferase activity does not predict low incidence of cardiovascular events: possible attenuation of cardioprotection associated with high HDL cholesterol. Atherosclerosis 2010, 208:537-542.
16. Scheven L., Joosten M.M., de Jong P.E., et al. The association of albuminuria with tubular reabsorption of uric acid: results from a general population cohort. J.Am. Heart Assoc. 2014, 3:e000613.
17. Cox D.R. Regression models and life-tables. J.R. Stat. Ser. B 1972, 34:187-220.
18. Therneau T.M., Grambsch P.M. Modeling Survival Data: Extending the Cox Model 2000, Springer, New York.
19. Easton D.F., Peto J., Babiker A.G. Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat. Med. 1991, 10:1025-1035.
20. Inker L.A., Schmid C.H., Tighiouart H., et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N.Engl. J. Med. 2012, 367:20-29.
21. WHO. Global database on body mass index [Internet]. Available at: [last accessed 09.12.14]. http://apps.who.int/bmi/index.jsp.
22. Pencina M.J., D'Agostino R.B., Steyerberg E.W. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Statistics Med. 2011, 30:11-21.
23. D'Agostino R.B., Vasan R.S., Pencina M.J., et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation 2008, 117:743-753.
24. Cook N.R., Paynter N.P., Eaton C.B., et al. Comparison of the Framingham and Reynolds risk scores for global cardiovascular risk prediction in the multiethnic women's health initiative. Circulation 2012, 125:1748-1756. S1741-1711.
25. Stone N.J., Robinson J., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the american college of cardiology/American heart association task force on practice guidelines. J.Am. Coll. Cardiol. 2013, 63:2889-2934.
26. Ridker P.M., Buring J.E., Rifai N., et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA 2007, 297:611-619.
27. Ridker P.M., Paynter N.P., Rifai N., et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds risk score for men. Circulation 2008, 118:2243-2251. 2244pp. following 2251.
28. Emdin M., Pompella A., Paolicchi A. Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation 2005, 112:2078-2080.
29. Franzini M., Corti A., Martinelli B., et al. Gamma-glutamyltransferase activity in human atherosclerotic plaques-biochemical similarities with the circulating enzyme. Atherosclerosis 2009, 202:119-127.
30. Franzini M., Paolicchi A., Fornaciari I., et al. Cardiovascular risk factors and gamma-glutamyltransferase fractions in healthy individuals. Clin. Chem. Lab. Med. 2010, 48:713-717.
31. Franzini M., Fornaciari I., Rong J., et al. Correlates and reference limits of plasma gamma-glutamyltransferase fractions from the Framingham heart study. Clin. Chim. Acta 2013, 417:19-25.
32. Ruhl C.E., Everhart J.E. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 2009, 136:477-485. e411.
33. Emerging Risk Factors, Collaboration, Kaptoge S., Di Angelantonio E., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375:132-140.
34. Jousilahti P., Rastenyte D., Tuomilehto J. Serum gamma-glutamyl transferase, self-reported alcohol drinking, and the risk of stroke. Stroke 2000, 31:1851-1855.
35. Lee D.H., Silventoinen K., Hu G., et al. Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women. Eur. Heart J. 2006, 27:2170-2176.
36. Martin I., Grotewiel M.S. Oxidative damage and age-related functional declines. Mech. Ageing Dev. 2006, 127:411-423.
37. Cusack B.J. Pharmacokinetics in older persons. Am. J. Geriatric Pharmacother. 2004, 2:274-302.
38. Musso G., Gambino R., Cassader M., et al. Ameta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010, 52:79-104.
39. Davey Smith G., Ebrahim S. Mendelian randomization: can genetic epidemiology contribute to understanding environmental determinants of disease?. Int. J. Epidemiol. 2003, 32:1-22.
40. Yuan X., Waterworth D., Perry J.R., et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am. J. Hum. Genet. 2008, 83:520-528.
41. Kamatani Y., Matsuda K., Okada Y., et al. Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat. Genet. 2010, 42:210-215.
42. Conen D., Vollenweider P., Rousson V., et al. Use of A Mendelian randomization approach to assess the causal relation of gamma-glutamyltransferase with blood pressure and serum insulin levels. Am. J. Epidemiol. 2010, 172:1431-1441.
43. Rhone D.P., White F.M. Effects of storage in the cold on activity of gamma-glutamyltransferase in serum. Clin. Chem. 1976, 22:103-104.